Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: A systematic review with meta-analysis

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 862-868

  Daïen, Claire Immediato ^a   Duny, Yohan ^b   Barnetche, Thomas ^c   Daurès, Jean Pierre ^b   Combe, Bernard ^a   Morel, Jacques ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; HEART PROTECTION; HUMAN; LIPID ANALYSIS; LONGITUDINAL STUDY; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; LIPIDS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860917295     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201148     Document Type: Article

References (63)

1. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73. (Pubitemid 34303796)
2. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40. (Pubitemid 36077769)
3. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
4. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011;70:929-34.
5. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7. (Pubitemid 34304256)
6. van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
7. Khovidhunkit W, Memon RA, Feingold KR, et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(Suppl 3):S462-72. (Pubitemid 30416122)
8. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482-7.
9. Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001;44:2761-7. (Pubitemid 34016195)
10. McDevitt H, Munson S, Ettinger R, et al. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002;4(Suppl 3):S141-52.
11. Dixon WG, Watson KD, Lunt M, et al.; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12. (Pubitemid 47502736)
12. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5. (Pubitemid 46707138)
13. Engvall IL, Tengstrand B, Brismar K, et al. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther 2010;12:R197.
14. Ferrante E, Vazzana N, Santilli F, et al. Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. Free Radic Biol Med 2010;49:857-64.
15. Jamnitski A, Visman IM, Peters MJ, et al. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 2010;69:1929-33.
16. Hansel B, Bruckert E. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy]. Ann Endocrinol (Paris) 2010;71:257-63.
17. Pollono EN, Lopez-Olivo MA, Lopez JA, et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:947-55.
18. Baldwin HM, Ito-Ihara T, Isaacs JD, et al. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis 2010;69:1200-7.
19. Meyer-Hermann M, Figge MT, Straub RH. Mathematical modeling of the circadian rhythm of key neuroendocrine-immune system players in rheumatoid arthritis: a systems biology approach. Arthritis Rheum 2009;60:2585-94.
20. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
21. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin Exp Rheumatol 2008;26:596-603.
22. Wijbrandts CA, van Leuven SI, Boom HD, et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1316-21.
23. Trocmé C, Marotte H, Baillet A, et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009;68:1328-33.
24. Popa C, van Tits LJ, Barrera P, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:868-72.
25. Kageyama Y, Takahashi M, Ichikawa T, et al. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008;26:73-80. (Pubitemid 351385258)
26. Ho S, Srinivasan U, Bevan M. Cholesterol crescents and plates in shoulder effusion of a rheumatoid patient. Rheumatology (Oxford) 2008;47:377-8. (Pubitemid 351267212)
27. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008;75:22-4.
28. Croce A, Firuzi O, Altieri F, et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 2007;21:303-14. (Pubitemid 47556810)
29. Saiki O, Takao R, Naruse Y, et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 2007;34:1997-2004. (Pubitemid 47548201)
30. Armstrong DJ. Anti-TNF alpha therapy, lipid profile and carotid intimal thickness. Rheumatology (Oxford) 2007;46:1626; author reply 1626-7.
31. Seriolo B, Paolino S, Ferrone C, et al. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol 2007;26:1799-800.
32. Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503-7. (Pubitemid 350032660)
33. Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66:958-61. (Pubitemid 46999801)
34. Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-8. (Pubitemid 47201685)
35. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:414-19. (Pubitemid 43989884)
36. Pérez-Galán MJ, Salvatierra-Ossorio J, Cáliz- Cáliz R, et al. [Influence of tumor necrosis alpha blockade with infliximab on lipid profile in patients with active rheumatoid arthritis]. Med Clin (Barc) 2006;126:757.
37. Dahlqvist SR, Engstrand S, Berglin E, et al. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006;35:107-11.
38. Kiortsis DN, Mavridis AK, Filippatos TD, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33:921-3.
39. Allanore Y, Kahan A, Sellam J, et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006;365:143-8. (Pubitemid 43196430)
40. Fuchs B, Schiller J, Wagner U, et al. The phosphatidylcholine/ lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem 2005;38:925-33. (Pubitemid 41316652)
41. Popa C, Barrea P, Netea MG, et al. Anti-TNF therapy and plasma HDL cholesterol concentration. Atherosclerosis 2005;182:375; author reply 377.
42. Capriotti T. The 'alphabet' of rheumatoid arthritis treatment. Medsurg Nurs 2004;13:420-8.
43. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5. (Pubitemid 40209122)
44. Fabris M, Tolusso B, Gremese E, et al. [Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients peripheral blood mononuclear cells stimulated with lipopolysaccharide]. Reumatismo 2004;56:94-103.
45. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5. (Pubitemid 40193632)
46. Min SY, Hwang SY, Jung YO, et al. Increase of cyclooxygenase-2 expression by interleukin 15 in rheumatoid synoviocytes. J Rheumatol 2004;31:875-83.
47. Alsalameh S, Amin RJ, Kunisch E, et al. Preferential induction of prodestructive matrix metalloproteinase-1 and proinflammatory interleukin 6 and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts via tumor necrosis factor receptor-55. J Rheumatol 2003;30:1680-90. (Pubitemid 36962443)
48. Cauza E, Cauza K, Hanusch-Enserer U, et al. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002;114:1004-7. (Pubitemid 36105546)
49. Badii M. National Meeting of the American College of Rheumatology. November 8-12, 1998, San Diego, California. Clin Invest Med 1999;22:63-4.
50. Lupia E, Montrucchio G, Battaglia E, et al. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996;26:1690-4. (Pubitemid 26283137)
51. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18. (Pubitemid 40995372)
52. Greenberg JD, Kremer JM, Curtis JR, et al.; CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
53. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8. (Pubitemid 44955879)
54. Bass KM, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16. (Pubitemid 23296487)
55. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
56. Karpouzas GA, Ahmadi N, Choi TY, et al. Lower prevalence and severity of 'vulnerable' coronary plaque in a-TNF-exposed asymptomatic patients with rheumatoid arthritis (abstract). Arthritis Rheum 2010;62(Suppl 10):1443.
57. Daien CI, Fesler P, Du Cailar G, et al. Etanercept induces a decrease in left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl 3):120.
58. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5. (Pubitemid 37026494)
59. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006;8:R82.
60. Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002;113:188-93. (Pubitemid 35245626)
61. Kerekes G, Soltész P, Dér H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009;28:705-10.
62. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008;59:1821-4.
63. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32.